Shionogi said on February 22 that it has obtained Taiwanese regulatory approval for its siderophore cephalosporin antibiotic Fetroja (cefiderocol) through its local subsidiary.The approval was granted for the treatment of complicated urinary tract infections, including pyelonephritis, and hospital-acquired pneumonia (including…
To read the full story
Related Article
- NDA for Cefiderocol Accepted in Taiwan: Shionogi
December 14, 2022
BUSINESS
- Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
- Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
- Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
- Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
- Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





